CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-08-18. AI was used for research and drafting; the existence of all 1 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v1.0.
Verdict No. 2721 · Search date 2026-08-18 · Methodology v1.0

Endoscopic sinus surgery,
does it really help with Improved symptoms and quality of life at six months in adults with chronic rhinosinusitis remaining symptomatic after appropriate medical therapy?

30-Second Summary
B
Evidence Grade B · 70 · Safety caution
Surgery substantially improved six-month symptoms, with the limitation of an unblinded patient-reported surgical comparison
Serious adverse events numbered five in four surgical participants, two in two clarithromycin participants, and three in three placebo participants; none were fatal. Bleeding, infection, anesthesia, and recovery burdens require individualized assessment.
What the
research shows
The grade is B. MACRO randomized 514 adults to surgery, clarithromycin, or oral placebo, with all groups continuing intranasal corticosteroids and saline irrigation. The adjusted six-month SNOT-22 difference for surgery versus placebo was -20.44 points (98.33% CI -26.42 to -14.46), and the entire interval exceeded the 8.9-point minimum important difference cited in the article. However, there was no sham surgery, and patients who knew whether they received surgery reported the primary outcome themselves.
What the
ads claim
Calling this a placebo-controlled surgery trial can obscure its structure. Identical oral capsules masked clarithromycin versus placebo only; surgery had no sham-procedure control. Marketing should stay within medically refractory surgical candidates and the six-month outcome tested.
*

Useful facts when choosing a product

  • The surgery arm continued intranasal corticosteroids and saline irrigation, so this was not surgery alone versus no treatment.
  • Oral placebo masked clarithromycin and was not a sham-surgery control.
  • The entire surgery-versus-placebo interval exceeded the article's cited 8.9-point SNOT-22 threshold.
ID

Chamgap Semantic Classification Code

Candidate index · review held

P.endoscopic-sinus-surgery-plus-intranasal-corticosteroids-and-saline-irrigation.intranasal.symptoms-and-quality-of-life-at-with-chronic-rhinosinusitis-remaining-symptomatic-after-appropriate-medical-therapy.improve.placebo

Procedures, devices and tests > Endoscopic sinus surgery plus intranasal corticosteroids and saline irrigation > Intranasal > symptoms and quality of life at with chronic rhinosinusitis remaining symptomatic after appropriate medical therapy > Improvement claim > Placebo

An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.

Download semantic index (JSON) · Codebook v1

Gap Measurement · Verdict 2721 · B 70
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

At 20 UK sites, 514 adults who remained symptomatic after appropriate medical therapy were assigned to surgery, 171; clarithromycin, 172; or oral placebo, 171. Assignment used an automated secure web system, and every group received intranasal corticosteroids and saline irrigation. Adjusted six-month SNOT-22 differences were -20.44 points for surgery versus placebo (98.33% CI -26.42 to -14.46, P<.0001), -18.13 for surgery versus clarithromycin (-24.26 to -11.99), and -3.11 for clarithromycin versus placebo (-8.56 to 2.33, P=.17). The randomized population was analyzed on an available-case basis. The NIHR Programme Grants for Applied Research funded the trial.

02

Why this is classified as B (70)

Large patient-reported symptom improvement and public funding are strengths, but one confirmatory trial with unmasked participants rating the primary outcome gives B with 70 points.

Counterpoint. B does not mean every patient needs surgery. It applies to the average six-month result in adults who remained symptomatic after appropriate medical therapy and were surgical candidates.

Rejudgment record. Cross-check applied — A publicly funded 514-participant randomized trial exceeded the minimum important difference, with caps for a single confirmatory trial and an unblinded patient-reported primary endpoint

Stored scoring profile
EndpointPSymptom or function itself is the target - including patient reports and performance tests
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

Stored derived and displayed grades match; this is not a current recalculation or validity check (B).

▦

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Six-month SNOT-22 improvement with surgeryBThe entire interval around the -20.44-point adjusted difference exceeded the 8.9-point threshold.
Six-month SNOT-22 improvement after three months of clarithromycinDVersus placebo, the difference was -3.11 points (98.33% CI -8.56 to 2.33), P=.17, without superiority.
✓

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Philpott C et al. 2025 MACROTwenty-center pragmatic three-arm randomized trial; antibiotic-placebo masked and surgery open-label514 randomized: 171 surgery, 172 clarithromycin, and 171 placeboNational Institute for Health and Care Research Programme Grants for Applied ResearchTotal SNOT-22 score six months after randomizationAdjusted surgery-placebo difference -20.44 points (98.33% CI -26.42 to -14.46, P<.0001); surgery-clarithromycin -18.13; clarithromycin-placebo -3.11 (P=.17)Direct publicly funded symptom evidence with an unblinded patient-reported surgical comparison
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-18).

Philpott C, Beard DJ, Saeedi E, et al. The clinical effectiveness of clarithromycin versus endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps (MACRO): a pragmatic, multicentre, three-arm, randomised, placebo-controlled phase 4 trial. Lancet. 2025;406(10506):926-939. PMID: 40885584. DOI: 10.1016/S0140-6736(25)01248-6. ISRCTN36962030; EudraCT 2018-001100-11.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
↗

Cite this verdict

Endoscopic sinus surgery x symptom improvement in medically refractory chronic rhinosinusitis Evidence Grade B card
[Chamgap] Endoscopic sinus surgery x symptom improvement in medically refractory chronic rhinosinusitis — Evidence Grade B·70. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/endoscopic-sinus-surgery-medical-therapy-refractory-chronic-rhinosinusitis-symptoms/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.
↑